Drug-resistant Trials

Trials for Gleevec, Sutent, Stivarga resistant GIST

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Phase I trials are included in this listing. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov. The drug name listed will be the most advanced available; i.e., brand name first or generic name and if neither of those are available, IND.

34 trials found

Avapritinib or Regorafenib

VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Phase:  3
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Summit Cancer Centers - Post Falls Post Falls ID USA
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
Fox Chase Cancer Center Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Centre Léon Bérard Lyon Rhone France
Asan Medical center Seoul Songpa-gu Republic of Korea
Mayo Clinic Cancer Center Phoenix AZ USA
Mayo Clinic, Jacksonville Jacksonville FL USA
University of Michigan Ann Arbor MI USA
Institut Gustave Roussy Villejuif Val de Narne France
Institut Bergonie Bordeaux Gironde France
Royal Marsden Hospital - Chelsea London UK
Lund University Hospital Lund Sweden
Monash Health Clayton Australia
H. Lee Moffit Cancer Center Tampa FL USA
Mayo Clinic, Rochester Rochester MN USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
Tennessee Oncology Nashville TN USA
Seoul National University Hospital Seoul Republic of Korea
Severance Hospital, Yonsei University Health System Seoul Republic of Korea
Summit Cancer Centers - Spokane Spokane WA USA
University Health Network Toronto ON Canada
 


Crenolanib besylate

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Phase:  3
Category:   D842V
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Sarcoma Oncology Center Santa Monica CA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Duke Cancer Institute Durham NC USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Centre Léon Bérard Lyon Rhone France
Hospital de La Timone Marseille France
Centre Val d'Aurele Montpellier France
CHU de Reimes - Hôpital Pontchaillou Reimes France
Institut Gustave Roussy Villejuif Val de Narne France
Helios Klinikum Berlin-Buch Berlin Germany
Universistatsklinikum Mannheim Mannheim Germany
Klinikum der Universitaet Muenchen-Grosshadem Campus Munich Germany
Istituto Nazionale Dei Tumori Milan Italy
Norwegian Radium Hospital Oslo Norway
Centrum Onkologii - Instytut Im. Sklodowskiej-Curie w Warszawie Warsaw Poland
Hospital Vall d'Hebron Barcelona Spain
Hospital Universitario Puerta de Hierro de Majadahonda Madrid Spain
Cambridge University Hospitals Cambridge UK
Royal Marsden Hospital - Chelsea London UK
Policlinico S. Orsola-Malpighi Bologna Italy
Institut Regina Elena / IFO Rome Italy
Candiolo Cancer Institute - FPO, IRCCS Turin Italy
Hospital Virgen del Rocio Sevilla Spain
Fundación Instituto Valenciano de Oncología Valencia Spain
Sheffield Teaching Hospital Sheffield UK
 


DCC-2618

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)
Phase:  3
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
Stanford University Palo Alto CA USA
Oregon Health & Science University Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Georgia Cancer Specialists Atlanta GA USA
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
 


AUY922

A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Phase:  2
Category:   HSP90 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
National Health Research Institute Taiwan
 


Cometriq

Ph II CABOGIST in GIST
Phase:  2
Category:   KIT/PDGFRA inhibitor + MET/VEGF inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Universitair Ziekenhuis Gasthuisberg Leuven Belgium
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
University College Hospital London UK
Christie Hospital NHS Trust Manchester Lancashire UK
Royal Marsden Hospital - Chelsea London UK
University Hospital Motol Prague Czechia
UniversitaetsMedizin Mannheim Mannheim Germany
Military Hospital - State Health Centre Budapest Hungary
Clatterbridge Centre for Oncology NHS Trust Bebington UK
 


Gleevec

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Phase:  2
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


Imatinib + MEK162

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:   KIT/PDGFRA inhibitor + MEK inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA
 


Opdivo + Yervoy

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Phase:  2
Category:   PD-1 inhibitor + CTLA-4 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
 


Pembrolizumab + Epacadostat

Epacadostat and Pembrolizumab in Patients With GISTEpacadostat and Pembrolizumab in Patients With GIST
Phase:  2
Category:   PD-1 + IDO1 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Michigan Ann Arbor MI USA
Columbia University - Herbert Irving Cancer Center New York NY USA
 


Iclusig

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)
Phase:  2
Category:   KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
 


Stivarga

Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib
Phase:  2
Category:   KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


Selumetinib

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Phase:  2
Category:   NF1 GIST
Conditions:  NF1 GIST

Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA
 


BBI503

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Phase:  1
Category:   Stem Cell inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Princess Margaret Hospital Toronto ON Canada
 


Binimetinib + Pexidartinib

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Phase:  1
Category:   KIT/PDGFRA inhibitor + MEK inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA
 


Avapritinib

Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Phase:  1
Category:   KIT/PDGFRA inhibitor + D842V inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Fox Chase Cancer Center Philadelphia PA USA
Oregon Health & Science University Portland OR USA
Leuven Cancer Institute, Catholic University Leuven Leuven Belgium
Erasmus Medical center Rotterdam Netherlands
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Centre Léon Bérard Lyon Rhone France
Royal Marsden Hospital - Chelsea London UK
Institut Gustave Roussy Villejuif Val de Narne France
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Istituto Nazionale Dei Tumori Milan Italy
Asan Medical center Seoul Songpa-gu Republic of Korea
Centrum Onkologii - Instytut Im. Sklodowskiej-Curie w Warszawie Warsaw Poland
Hospital Vall d'Hebron Barcelona Spain
MD Anderson Cancer Center Houston TX USA
Sarcoma Oncology Center Santa Monica CA USA
 


Intuvax

A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors (GIST)
Phase:  1
Category:   Immune stimulate
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Karolinska University Hospital Stockholm Sweden
 


NeoBOMB1

MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
Phase:  1
Category:   GRPR Antagonst
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Medizinische Universitat Innsbruk - Universitatklinil fur Nuklearmedizin Innsbruck Austria
 


Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
Phase:  1/2
Category:  
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
Stanford University Medical Center Palo Alto CA USA
Mayo Clinic Cancer Center Phoenix AZ USA
 


Inlyta + Keytruda

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
Phase:  2
Category:   KIT/PDGFRa inhibitor + PD-1 inhibitor
Conditions:  Sarcoma

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
 


Opdivo + Yervoy

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma
Phase:  2
Category:   PD-1 inhibitor + CTLA-4 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Washington University School of Medicine St. Louis MO USA
North Shore University Health Systems Evanston IL USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Dana Farber Cancer Institute Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
 


Keytruda + Cyclophosphamide

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)
Phase:  2
Category:   Immunotherapeutic
Conditions:  Sarcoma

Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Centre Léon Bérard Lyon Rhone France
Institut Paoli-Calmette Marseille Bouches du Rhone France
St. Herblain Nantes Loire Atlantique France
Institut Claudius Regaud Toulouse France
Institut Gustave Roussy Villejuif Val de Narne France
Instituit Curie Paris France
 


Zelboraf

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)
Phase:  2
Category:   BRAF inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Hopital Saint-Joseph Service Oncologie Paris France
 


CB-839

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase:  1
Category:   SDH-directed
Conditions:  Solid Tumors

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
University of Pennsylvania Philadelphia PA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA
Stanford University Medical Center Palo Alto CA USA
Florida Cancer Specialists Sarasota FL USA
Tennessee Oncology Nashville TN USA
Emory Winship Cancer Institute Atlanta GA USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
Naytional Cancer Institute Bethesda MD USA
 


DCC-2618

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
Princess Margaret Hospital Toronto ON Canada
Dana Farber Cancer Institute Boston MA USA
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
Stanford Cancer Center Palo Alto CA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Oregon Health & Science University Portland OR USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Fox Chase Cancer Center Philadelphia PA USA
Huntsman Cancer Institute Salt Lake City UT USA
Royal Marsden Hospital - Chelsea London UK
 


HER-2 B Cell Peptide Vaccine

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase:  1
Category:   Immune stimulate
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Ohio State University Comprehensive Cancer Center Columbus OH USA
 


Imatinib + Ipilimumab

Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase:  1
Category:   KIT/PDGFRA inhibitor + CTLA4 inhibitor
Conditions:  Advanced Cancer

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
 


PLX9486 + PLX3397

A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST
Phase:  1
Category:   KIT inhibitor + Tumor Associated Macrophage inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Karmanos Cancer Institute Detroit MI USA
Memorial Sloan-Kettering Cancer Center New York NY USA
University of Michigan Ann Arbor MI USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
 


XmAb18087

A Study of XmAb®18087 in Subjects With NET and GIST
Phase:  1
Category:   SSTR2 + CD3 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Emory Winship Cancer Institute Atlanta GA USA
City of Hope Duarte CA USA
MD Anderson Cancer Center Houston TX USA
 


PDR001

Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase:  1/2
Category:   PD-1 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Massachusetts General Hospital Boston MA USA
Oregon Health & Science University Portland OR USA
Sarah Cannon Research Institute Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Huntsman Cancer Institute Salt Lake City UT USA
Site name unknown, Toronto Toronto Canada
Institut Gustave Roussy Villejuif Val de Narne France
Site name unknown, Amsterdam Amsterdam Netherlands
Site name unknown, Leiden Leiden Netherlands
Hospital Vall d'Hebron Barcelona Spain
Site name unknown - Taipei Taipei Taiwan
Institut Claudius Regaud Toulouse France
Site name unknown - Madrid 28050 Madrid Spain
Site name unknown - Tainan Tainan City Taiwan
Hôpital Saint-Louis Paris France
Site name unknown, Ulm, Germany 89081 Ulm Germany
Norwegian Radium Hospital Oslo Norway
Site name unknown, Milan Milan Italy
Site name unknown Napoli 80131 Napoli Italy
 


Cometriq

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Phase:  2
Category:   KIT/PDGFRA inhibitor + MET/VEGF inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA
 


34 trials found